Eledon Pharmaceuticals Inc (ELDN)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

19900 MACARTHUR BLVD. IRVINE, CA 92612

Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company’s lead compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as B cells, macrophages, and dendritic cells. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which is especially important for autoimmune diseases and in the transplant setting. Furthermore AT-1501 is an IgG1 antibody specifically engineered to cripple the Fc effector function to potentially improve safety, as well as potentially provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other approaches.

Data as of 2021-08-02 08:42:10 -0400
Market Cap92.85 Million Shares Outstanding14.307 Million Avg 30-day Volume75.868 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.78776 52-week High/Low27.32 / 6.02 Next Earnings Date2021-08-12 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from ELDN instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 35 22 59.09% 22 (1.29%) 13 (0.75%) 69.23%
13F shares: 8.318 Million 5.768 Million 44.19% 6.435 Million 4.598 Million 39.94%
% Ownership
New Positions: 19 8 137.5% 12 6 100.0%
Increased Positions 5 7 -28.57% 1 3 -66.67%
Closed Positions 6 7 -14.29% 3 2 50.0%
Reduced Positions 3 6 -50.0% 3 4 -25.0%
Total Calls
Total Puts
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ELDN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ELDN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

13 Thousand total shares from 2 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HILLSON JAN

  • Director
0 2021-07-01 1

LITTLE PAUL SEAN CHIEF FINANCIAL OFFICER

  • Officer
10,000 2021-06-11 2

GROS DAVID-ALEXANDRE C CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
3,000 2021-06-09 3

SMITH BRYAN E. SEE REMARKS

  • Officer
158,500 2021-05-03 2

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BVF I GP LLC

BIOTECHNOLOGY VALUE FUND II LP

BVF II GP LLC

BIOTECHNOLOGY VALUE TRADING FUND OS LP

BVF PARTNERS OS LTD.

BVF GP HOLDINGS LLC

BVF INC/IL

LAMPERT MARK N

  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
No longer subject to file 2020-12-22 2

LEE JUNE

  • Director
0 2020-12-08 1

ORBIMED ISRAEL GP LTD.

ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP

  • 10% Owner
No longer subject to file 2020-12-02 1

LOGOS GLOBAL MANAGEMENT LP

  • 10% Owner
145,000 2020-10-30 2

OGIER WALTER C

  • Director
0 2020-09-14 1

PERRIN STEVEN SEE REMARKS

  • Officer
  • Director
0 2020-09-14 1

MCBRIDE JOHN S.

  • Director
0 2020-09-11 1

KATKIN KEITH

  • Director
0 2020-09-11 1

LYONS GARY A

  • Director
0 2020-09-11 1

KUWAHARA JON SEE REMARKS

  • Officer
0 2020-09-11 1

TURKEL CATHERINE C. PRESIDENT

  • Officer
0 2020-03-19 0

FLESHER GREGORY J. CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2020-03-19 0

CHIMOVITS EREZ

  • Director
  • 10% Owner
0 2020-01-14 0

COHEN CHERYL

  • Director
0 2019-07-11 0

LIFESCI INDEX PARTNERS LLC

YOOK PAUL

  • 10% Owner
No longer subject to file 2019-04-30 0

MORRISON JODIE POPE

  • Director
0 2017-06-30 0

OCAMPO CHRISTINE SEE REMARKS

  • Officer
0 2017-05-24 0

BARBERICH TIMOTHY J

0 2016-06-15 0

HARRISON SETH LORING

0 2016-06-15 0

KESSLER DAVID A.

0 2016-06-15 0

YANCHIK JOSEPH A., III

0 2016-06-15 0

BUCKLEY STEPHEN JR.

0 2016-06-15 0

KALOWSKI LEE CHIEF FINANCIAL OFFICER

0 2015-12-15 0

FERRANTE KAREN JEAN HEAD RES. & DEV. & CHIEF MED.

0 2015-12-15 0

QUIRK GERALD E GENERAL COUNSEL, EXECUTIVE VP

0 2015-12-15 0

NOVARTIS BIOVENTURES LTD

NOVARTIS AG

  • 10% Owner
4,493,458 2015-07-15 0

APPLE TREE PARTNERS II - ANNEX, L.P.

  • Director
  • 10% Owner
3,568,438 2014-09-22 0

APPLE TREE PARTNERS II LP

  • Director
  • 10% Owner
4,218,641 2014-09-22 0

SATTER MUNEER A

  • 10% Owner
No longer subject to file 2014-09-22 0

APPLE TREE PARTNERS IV, L.P.

  • Director
  • 10% Owner
125,000 2014-09-22 0

PLATT JON B.

  • 10% Owner
0 2014-09-16 0

QBF NO. 1 PTY LTD AS TRUSTEE FOR QUEENSLAND BIOCAPITAL FUND NO. 1

  • 10% Owner
0 2014-09-16 0

QBF NO. 2 PTY LTD AS TRUSTEE FOR QUEENSLAND BIOCAPITAL FUND NO. 2

  • 10% Owner
0 2014-09-16 0

STEWART SUSAN B.

  • 10% Owner
0 2014-09-16 0

THOMAS ROBERT BAIN

  • 10% Owner
0 2014-09-16 0

WADE DENIS NEWELL

  • 10% Owner
0 2014-09-16 0

WARMAN INVESTMENTS PTY. LTD.

  • 10% Owner
0 2014-09-16 0

WILLIAMS MARTIN D

  • 10% Owner
168,850 2014-09-16 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

LITTLE PAUL SEAN - Officer CHIEF FINANCIAL OFFICER

2021-06-14 17:24:30 -0400 2021-06-11 P 10,000 $8.87 a 10,000 direct -5.3988 -6.5031 -23.4356 0.0 1 -24.1718 30

GROS DAVID-ALEXANDRE C - Director - Officer CHIEF EXECUTIVE OFFICER

2021-06-10 17:25:51 -0400 2021-06-09 P 3,000 $8.01 a 3,000 direct -8.5324 -10.2389 -28.7827 0.0 1 -28.7827 31

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ELEDON PHARMACEUTICALS INC ELDN 2021-08-03 15:45:03 UTC -9.5519 9.6119 90000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-03 15:15:03 UTC -9.5519 9.6119 90000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-03 14:45:04 UTC -9.5519 9.6119 90000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-03 14:15:03 UTC -9.5519 9.6119 90000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-03 13:45:03 UTC -9.5519 9.6119 90000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-03 13:15:03 UTC -9.5519 9.6119 90000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-03 12:45:03 UTC -9.5519 9.6119 90000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-02 22:15:03 UTC -9.5519 9.6119 70000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-02 21:45:03 UTC -9.5519 9.6119 70000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-02 21:15:03 UTC -9.5519 9.6119 70000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-02 20:45:03 UTC -9.5519 9.6119 70000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-02 20:15:03 UTC -9.5519 9.6119 70000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-02 19:45:03 UTC -9.5519 9.6119 70000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-02 19:15:03 UTC -9.5519 9.6119 70000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-02 18:45:03 UTC -13.2816 13.3416 70000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-02 18:15:03 UTC -13.2816 13.3416 70000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-02 17:45:03 UTC -13.2816 13.3416 70000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-02 17:15:03 UTC -13.2816 13.3416 70000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-02 16:45:03 UTC -13.2832 13.3632 70000
ELEDON PHARMACEUTICALS INC ELDN 2021-08-02 16:15:03 UTC -13.2832 13.3632 70000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments